Ocular Hypertension Pharmaceutical and Healthcare Pipeline Review H2

Pune, India, 24th August 2017: WiseGuyReports announced addition of new report, titled “Ocular Hypertension – Pipeline Review, H2 2017”.

Summary

Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea and bleeding at the optic nerve head. Treatment includes eye drops to reduce intraocular pressure.

 

GET SAMPLE REPORT @https://www.wiseguyreports.com/sample-request/1927009-ocular-hypertension-pipeline-review-h2-2017       

 

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Ocular Hypertension – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Ocular Hypertension (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 7, 14, 3 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

 

Ocular Hypertension (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Ocular Hypertension (Ophthalmology)

 

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 

Table of Content: Key Points

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Ocular Hypertension – Overview 6

Ocular Hypertension – Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Ocular Hypertension – Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Ocular Hypertension – Companies Involved in Therapeutics Development 23

Aerie Pharmaceuticals Inc 23

Alcon Laboratories Inc 23

Allergan Plc 24

Bausch & Lomb Inc 24

Can-Fite BioPharma Ltd 25

D. Western Therapeutics Institute Inc 25

F. Hoffmann-La Roche Ltd 26

Ironwood Pharmaceuticals Inc 26

Laboratoires Thea SA 27

Laboratorios Sophia SA de CV 27

Neurim Pharmaceuticals Ltd 28

NicOx SA 28

Ocular Therapeutix Inc 29

Santen Pharmaceutical Co Ltd 30

Senju Pharmaceutical Co Ltd 30

…Continued        

 

ACCESS REPORT @ https://www.wiseguyreports.com/reports/1927009-ocular-hypertension-pipeline-review-h2-2017                         

 

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports                                                                  

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts    

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: sales@wiseguyreports.com
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India
Website: www.wiseguyreports.com